Stereotaxis (STXS) AI Stock Analysis

• Market Cap: $179.74M
• Dividend Yield: N/A
• Average Volume (3M): 311.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.67
• Revenue Growth: 1.50%
• EPS Growth: -20.00%
• Country: US
• Employees: 139
• Sector: Healthcare
• Sector Strength: 44
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.07
• Shares Outstanding: 86,000,850
• 10 Day Avg. Volume: 235,241
• 30 Day Avg. Volume: 311,737
• PEG Ratio: 0.60
• Price to Book (P/B): 27.85
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.51
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $4.67
• Price Target Upside: 123.44% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 64 Neutral
• Price Target: ―

Stereotaxis demonstrates a strong market position with promising revenue growth and strategic product launches. However, profitability challenges, negative cash flows, and market uncertainties weigh down its financial stability. The technical indicators show positive momentum, but valuation remains a concern due to lack of profitability and dividends.

Positive Factors

Earnings

STXS posted 1Q revenue of $7.5M, beating the Street's $6.9M estimate by a comfortable margin.

Partnerships

STXS’s acceptance into the NVIDIA Connect program marks a pivotal milestone in its long-term innovation strategy, enabling future advanced AI integration to enhance robotic precision, automation, and decision support.

Product Innovation

GenesisX, Stereotaxis’ mobile robot that can be installed in days rather than months, has launched in Europe and is expected to be FDA cleared soon.

Negative Factors

Cash Flow

Free cash flow was positive in the quarter, at $1.3M, with no debt on the balance sheet.

Financial Performance

The 4Q operating loss was $7.6M, while the net loss was $7.5M.

Revenue Guidance

The company has a system backlog worth $15M, supporting the system revenue guidance for 2025.

Stereotaxis Business Overview & Revenue Model

Company Description

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.

How the Company Makes Money

Stereotaxis generates revenue primarily through the sale of its robotic navigation systems, related disposable interventional devices, and ongoing service contracts. A significant portion of its income is derived from the installation of its systems in hospitals and medical facilities, where it also earns revenue from the sale of consumables and accessories required for each procedure. The company also engages in partnerships with healthcare providers and institutions to expand its reach and enhance its product offerings. Service agreements, including maintenance and support for the installed systems, provide a recurring revenue stream, contributing to the company's financial stability.

Stereotaxis Financial Statement Overview

Summary

Stereotaxis demonstrates consistent revenue but struggles with profitability due to high operational costs, resulting in negative net income. The balance sheet shows balanced leverage with a debt-to-equity ratio of 0.99 but limited equity. Cash flow challenges persist, with negative free cash flow reflecting the need for improved cash management.

Income Statement

Stereotaxis has shown marginal revenue growth over the years but faces challenges in profitability. The gross profit margin remains robust at around 54.2% for 2024, but the company continues to operate at a net loss, with a net profit margin of -94.2% in 2024. This indicates high operational costs relative to revenue, leading to negative EBIT and EBITDA margins, which suggest a need for cost management and strategic improvements.

Balance Sheet

The debt-to-equity ratio for 2024 stands at approximately 0.99, showing a balanced leverage profile. However, the equity ratio is relatively low at 13.0%, indicating limited asset backing by equity. The company’s return on equity is negative due to sustained losses, highlighting potential financial stability concerns.

Cash Flow

Free cash flow has seen a slight improvement but remains negative, reflecting cash outflow challenges. The operating cash flow to net income ratio is unfavorable due to negative cash flows, indicating issues in converting revenue into cash. The free cash flow to net income ratio also highlights cash generation difficulties, requiring strategic cash flow management.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
25.14M	26.92M	26.77M	28.15M	35.02M	26.63M
	Gross Profit
14.12M	14.59M	14.86M	18.47M	23.23M	18.97M
	EBIT
-22.42M	-24.74M	-21.84M	-18.78M	-12.89M	-6.71M
	EBITDA
-21.52M	-24.74M	-21.24M	-18.35M	-12.78M	-6.59M
	Net Income Common Stockholders
-21.57M	-25.35M	-20.71M	-19.15M	-8.44M	-6.45M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
9.04M	12.22M	19.82M	28.43M	38.74M	43.94M
	Total Assets
22.44M	46.72M	41.91M	53.41M	60.98M	55.46M
	Total Debt
5.59M	6.01M	5.49M	5.86M	6.11M	4.45M
	Net Debt
-3.45M	-6.21M	-14.33M	-2.73M	-32.63M	-39.49M
	Total Liabilities
17.11M	35.29M	19.99M	21.48M	21.56M	15.23M
	Stockholders Equity
5.33M	6.08M	21.92M	31.93M	39.42M	40.23M
Cash Flow		Free Cash Flow
-12.23M	-8.53M	-9.51M	-10.79M	-4.34M	-3.58M
	Operating Cash Flow
-12.20M	-8.50M	-9.14M	-8.41M	-2.95M	-3.51M
	Investing Cash Flow
76.00K	74.00K	19.77M	-22.09M	-1.40M	-70.90K
	Financing Cash Flow
164.00K	297.00K	81.00K	220.00K	547.41K	17.34M

Stereotaxis Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.09
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STXS, the sentiment is Neutral. The current price of 2.09 is above the 20-day moving average (MA) of 2.05, above the 50-day MA of 1.91, and above the 200-day MA of 2.07, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 52.77 is Neutral, neither overbought nor oversold. The STOCH value of 58.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for STXS.

Stereotaxis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATR	78 Outperform	$10.44B	28.90	15.15%	1.11%	0.34%	17.27%
MMSI	76 Outperform	$5.80B	48.46	9.16%	―	8.24%	18.54%
HOLX	66 Neutral	$12.58B	23.84	11.77%	―	1.66%	21.95%
ATRC	65 Neutral	$1.60B	―	-8.38%	―	15.79%	-1.20%
STXS	64 Neutral	$179.74M	―	-179.82%	―	1.50%	-20.00%
STAA	54 Neutral	$953.38M	55.81	-19.14%	―	-14.44%	-557.38%
Sector *	53 Neutral	$5.24B	3.07	-43.58%	2.80%	16.87%	-0.11%

Stereotaxis Corporate Events

Stereotaxis Holds 2025 Annual Shareholders Meeting

On May 15, 2025, Stereotaxis held its Annual Meeting of Shareholders, where a 59% quorum was achieved with 63,792,419 shares represented. During the meeting, shareholders elected two Class III directors to serve until the 2028 Annual Meeting and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2025. The election of directors was determined by a plurality of votes, and the proposal to ratify the accounting firm was passed by a majority of the outstanding shares.

The most recent analyst rating on (STXS) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Stereotaxis stock, see the STXS Stock Forecast page.

Spark’s Take on STXS Stock

According to Spark, TipRanks’ AI Analyst, STXS is a Neutral.

Stereotaxis demonstrates a strong market position with promising revenue growth and strategic product launches. However, profitability challenges, negative cash flows, and market uncertainties weigh down its financial stability. The technical indicators show positive momentum, but valuation remains a concern due to lack of profitability and dividends.

To see Spark’s full report on STXS stock, click here.